Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Tumor Biology

Abstract LB-258: Smoothening the way for human leukemia stem cell inhibition in chronic myeloid leukemia

Annelie E. Abrahamsson-Schairer, Alice Shih, Ifat Geron, Tannishtha Reya, Wendy Levin, Todd VanArsdale and Catriona H. Jamieson
Annelie E. Abrahamsson-Schairer
1UCSD Moores Cancer Center, La Jolla, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alice Shih
1UCSD Moores Cancer Center, La Jolla, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ifat Geron
1UCSD Moores Cancer Center, La Jolla, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tannishtha Reya
2Duke University, Durham, NC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wendy Levin
3Pfizer, La Jolla, CA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Todd VanArsdale
3Pfizer, La Jolla, CA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catriona H. Jamieson
1UCSD Moores Cancer Center, La Jolla, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM10-LB-258 Published April 2010
  • Article
  • Info & Metrics
Loading
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC

Abstract

Chronic myeloid leukemia (CML) progresses from a chronic phase (CP) state that harbors the BCR-ABL fusion gene, to CML blast crisis (BC), characterized by activation of -catenin within granulocyte-macrophage progenitors (GMP) (Jamieson et al, NEJM 2004). BC CML GMP serially transplant leukemia in vivo and form myeloid sarcomas (Abrahamsson et al, PNAS 2009). Wnt, GSK3 and Shh family molecules are implicated in driving leukemia progression and because GSK3 is a negative regulator of both Wnt and Shh signaling pathways, we evaluated whether GSK3 deregulation activates -catenin and Gli simultaneously. We investigated whether treatment with a SMO antagonist in combination with dasatinib decreases human BC CML engraftment in vivo.

BC CML tumor cells were treated for 0 and 7 days in vitro with vehicle (DMSO) or SMO antagonist (Pfizer; PF-04449913) and harvested for Q-PCR analysis. FACS-purified BC CML progenitors (CD34+CD38+Lin-PI−) were transplanted intrahepatically into newborn RAG2−/− c−/− mice and serially transplanted for propagation of tumors. Harvested tumors were then CD34-selected and transplanted to tertiary recipients (1×105 cells per mouse). Mice were treated for 14 days starting at 8 weeks of age. Mice were dosed once daily by oral gavage with 200µl of drug or vehicle (50% PEG in HBSS). The treatment included PF-04449913 (100mg/kg) with or without dasatinib (50mg/kg). After treatment the percentage of LSC (CD34+CD38+CD45RA+CD123+Lin-PI−) was determined by FACS analysis of the bone marrow and liver and number of tumors evaluated. BC CML progenitors harbors an up regulation of Gli mRNA and a downregulation of Ptch1 mRNA (n=3) compared to normal cord blood. Gli mRNA expression decreases following in vitro treatment with PF-04449913. Treatment with PF-04449913 alone in human BC CML LSC transplanted mice (n=3 exp., n=15 mice) does not significantly inhibit engraftment compared with vehicle (n=3 exp., n= 27 mice). Although dasatinib alone decreases tumor formation (P≤0.05), it does not eradicate the LSC in the liver or bone marrow (n=3 exp., n=20 mice). Combination treatment with PF-04449913 and dasatinib revealed a significant decrease in LSC engraftment in livers (P≤0.05) compared with the PF-04449913 or dasatinib alone. The combination treatment completely eradicated the LSC capability of tumor formation (0.0) in secondary recipients (n=5) compared with dasatinib that had an average of 1.8 tumors (n=6), PF-04449913 that had an average of 4.9 (n=7) and vehicle group that had 3.8 tumors (n=13). Colony formation assays were performed with cord blood CD34+ progenitors (n=3 samples) and no toxicity could be seen with PF-04449913 (1µM) compared with vehicle. There was no significant inhibition of normal CD34+ colony replating following PF-04449913 compared with vehicle treatment.

A phase I clinical trial with PF-04449913 in combination with dasatinib is currently being executed for advanced phase CML.

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-258.

  • ©2010 American Association for Cancer Research
Back to top
Cancer Research: 70 (8 Supplement)
April 2010
Volume 70, Issue 8 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract LB-258: Smoothening the way for human leukemia stem cell inhibition in chronic myeloid leukemia
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract LB-258: Smoothening the way for human leukemia stem cell inhibition in chronic myeloid leukemia
Annelie E. Abrahamsson-Schairer, Alice Shih, Ifat Geron, Tannishtha Reya, Wendy Levin, Todd VanArsdale and Catriona H. Jamieson
Cancer Res April 15 2010 (70) (8 Supplement) LB-258; DOI: 10.1158/1538-7445.AM10-LB-258

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract LB-258: Smoothening the way for human leukemia stem cell inhibition in chronic myeloid leukemia
Annelie E. Abrahamsson-Schairer, Alice Shih, Ifat Geron, Tannishtha Reya, Wendy Levin, Todd VanArsdale and Catriona H. Jamieson
Cancer Res April 15 2010 (70) (8 Supplement) LB-258; DOI: 10.1158/1538-7445.AM10-LB-258
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Tumor Biology

  • Abstract SY34-04: Do we need to know what pO2 hypoxia is
  • Abstract SY28-04: Rational incorporation of novel agents into multimodality treatment of glioma and neuroblastoma
  • Abstract SY28-02: Connections in the BRCA1-BRCA2 pathway of homologous recombination: Implications for breast cancer development and treatment
Show more 3

Poster Presentations - Late-Breaking Abstracts

  • Abstract LB-301: PLK1 inhibitor targets mismatch repair-deficient temozolomide-resistant tumors
  • Abstract LB-254: Thymidylate synthase gene polymorphisms is negatively associated with gastric cancer survival
  • Abstract LB-243: Precision medicine: Lung biomarkers
Show more 3

Late-Breaking Poster Presentations - Cancer Stem Cells

  • Abstract LB-189: A role of Notch2 in quiescence of mammary stem/progenitor cells
  • Abstract LB-203: Mathematical modeling of the dynamic interaction between cancers stem cells and non-stem cancer cells and its potential clinical implication
  • Abstract LB-191: Glioblastomas can originate from neurons in the CNS
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement